Podcasts about metastatic

Spread of a disease inside a body

  • 356PODCASTS
  • 1,237EPISODES
  • 27mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jan 23, 2023LATEST
metastatic

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about metastatic

Show all podcasts related to metastatic

Latest podcast episodes about metastatic

Real Pink
Episode 209: How Public Policy is Bridging Gaps for Black Breast Health

Real Pink

Play Episode Listen Later Jan 23, 2023 32:16


Susan G. Komen's Center for Public Policy identifies the public policy issue areas where Komen's voice can provide the greatest potential for achieving the mission to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. We are excited to discuss the work Komen is doing to drive policies that will bridge gaps that affect the Black community with Molly Guthrie, Komen's Vice President for Policy & Advocacy, and Janice Parker, a 10-year breast cancer survivor and advocate.

Real Pink
Episode 208: 20 Years Since Her Diagnosis, Julie is Stronger Than Ever

Real Pink

Play Episode Listen Later Jan 16, 2023 21:19


Julie Untener remembers the day like it was yesterday… 20 years ago, in January of 2003, Julie decided to do a breast exam. She'd been vigilant about getting her yearly mammograms, so on on this particular day, when she felt a marble on her left side, Julie knew something wasn't quite right. She went to the doctor to get additional scans, and was eventually diagnosed with breast cancer. After undergoing six rounds of chemo, helping her sisters through their own mastectomies, and learning a lot of lessons along the way… Julie is here today to share her breast cancer story and what she's learned over the last 20 years. Julie, welcome to the show!

Real Pink
Episode 207: Finding Empowerment After Breast Cancer

Real Pink

Play Episode Listen Later Jan 9, 2023 29:30


On this show, we often talk about how lives are changed after breast cancer, how a survivor's life takes on a new normal. There can be many challenges that come along with that – from self-esteem to navigating relationships, and even sometimes the shifting of life priorities. Today's guest has been through a whole host of changes in the decade since her breast cancer diagnosis, including a divorce and a career shift that brought her to Komen to make a difference in the lives of others facing breast cancer. Here today to share how she was able to find empowerment following her breast cancer diagnosis is Nikki Panico. Nikki exemplifies the power of living as her truest self and believing that she can do anything…and she has some great stories of doing just that. She is a shining light and I want to bottle her energy up and share with all of you, so let's get started.

Research To Practice | Oncology Videos
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Managing Metastatic Urothelial Bladder Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 5, 2023 55:57


Featuring an interview with Dr Scott Tagawa, including the following topics: Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00) Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55) Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21) Case: A man in his mid 60s with FGFR-altered metastatic UBC (49:45) CME information and select publications

Prostate Cancer Update
Oncology Today with Dr Neil Love: Managing Metastatic Urothelial Bladder Cancer

Prostate Cancer Update

Play Episode Listen Later Jan 5, 2023 56:08


Featuring a discussion on current treatments for metastatic urothelial bladder cancer with Dr Scott Tagawa, moderated by Dr Neil Love.

Oncology Today with Dr Neil Love
Managing Metastatic Urothelial Bladder Cancer with Dr Scott Tagawa

Oncology Today with Dr Neil Love

Play Episode Listen Later Jan 5, 2023 56:00


Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMetastaticBladderCancer22).

Research To Practice | Oncology Videos
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Managing Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 5, 2023 29:08


Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics: Managing patients with FGFR-altered urothelial bladder cancer (UBC) (0:00) Antibody-drug conjugates as treatment for metastatic UBC (10:22) Strategies for using systemic therapies to treat metastatic UBC (27:31) CME information and select publications

Real Pink
Episode 206: Understanding Your Breast Cancer Risk

Real Pink

Play Episode Listen Later Jan 2, 2023 28:42


Whether you're concerned about your risk of breast cancer, have a history of breast cancer or other cancers in your family, or are curious about genetic testing, the first step is learning more about risk. Everyone is at risk of breast cancer, and some of us are at a higher risk than others. We are pleased to have Dr. Anne Marie McCarthy, an assistant professor of epidemiology from the University of Pennsylvania School of Medicine here today to help educate us about breast cancer risk so we can feel empowered to make important breast care decisions and take charge of our health. Dr. McCarthy's research is focused on developing ways to identify women who are at a high risk for aggressive breast cancer. Dr. McCarthy, welcome to the show!

PaperPlayer biorxiv neuroscience
Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Dec 30, 2022


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.29.522199v1?rss=1 Authors: Diaz-delCastillo, M., Palasca, O., Nemler, T. T., Thygesen, D. M., Chavez-Saldana, N. A., Vazquez-Mora, J. A., Ponce Gomez, L. Y., Juhl Jensen, L., Evans, H., Andrews, R. E., Mandal, A., Neves, D., Mehlen, P., Caruso, J. P., Dougherty, P. M., Price, T. J., Chantry, A., Lawson, M. A., Andersen, T. L., Jimenez-Andrade, J. M., Heegaard, A.-M. Abstract: Multiple myeloma (MM) is a neoplasia of B plasma cells that often induces bone pain. However, the mechanisms underlying myeloma-induced bone pain (MIBP) are mostly unknown. Using a syngeneic MM mouse model, we show that periosteal nerve sprouting of calcitonin-gene related protein (CGRP+) and growth associated protein 43 (GAP43+) fibres occurs concurrent to the onset of nociception and its blockade provides transient pain relief. MM patient samples also showed increased periosteal innervation. Mechanistically, we investigated MM induced gene expression changes in the dorsal root ganglia (DRG) innervating the MM-bearing bone and found alterations in pathways associated with cell cycle, immune response and neuronal signalling. The MM transcriptional signature was consistent with metastatic MM infiltration to the DRG, a never-before described feature of the disease that we further demonstrated histologically. In the DRG, MM cells caused loss of vascularization and neuronal injury, which may contribute to late-stage MIBP. Interestingly, the transcriptional signature of a MM patient was consistent with MM cell infiltration to the DRG. Overall, our results suggest that MM induces a plethora of peripheral nervous system alterations that may contribute to the failure of current analgesics and suggest neuroprotective drugs as appropriate strategies to treat early onset MIBP. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Real Pink
Episode 205: Increasing Health Care Workforce Diversity

Real Pink

Play Episode Listen Later Dec 26, 2022 24:58


Susan G. Komen's approach to creating a health equity revolution through Stand for H.E.R. includes tailored interventions such as workforce development to increase diversity and improve cultural sensitivity of health care workers. We are thrilled to welcome Dr. Tracy Battaglia (Bit-tag-lea) from Boston University and Kyandra (Key-andra) Fox from Komen's Patient Navigation training team to discuss this important topic. Welcome to the show, Tracy and Kyandra!

The Shameless Mom Academy
714: Viki Zarkin: The Only 12 Year Survivor of Stage 4 Metastatic Cancer

The Shameless Mom Academy

Play Episode Listen Later Dec 26, 2022 47:59


Viki Zarkin was diagnosed with cancer in 2011, has been living with Stage 4 metastatic cancer for over 10 years, and is the only person in the world alive with this aggressive illness. She was diagnosed in her 40s when her doctor first told her to go home and get her affairs in order and at the time, she had 2 small children at home. Viki spent the next several years fighting for her life, advocating for herself, navigating through the healthcare world, and following her gut. Today, Viki is a beacon of hope for others, she's a motivational speaker and coach on a national level and a successful author. Viki inspires women to change the way they have been programmed to think and emphasizes the importance of starting with young women on how to believe in themselves, challenge the status quo, find their voices and listen to their hearts.  Listen in to hear Viki share: Her diagnosis of stage 4 metastatic cancer 12 years ago What happened when she grabbed her doctor by the neck when her doctor suggested she might not survive her diagnosis What it was like working through stage 4 cancer treatment with children ages 8 and 11 What her life is like being treated every 28 days with chemo to manage her cancer The side effects of long-term cancer treatments What it has been like to mother while also managing cancer for 12 years Her bargain with God and how that has played out  How to navigate power differentials in healthcare Links mentioned: Register for my Plan & Prep Pajama Party on January 23rd: shamelessmom.com/pajamaparty Connect with Viki: iamtheone.com/ Viki on FB Viki on IG Sponsor info and promo codes: Please find our sponsor information here: shamelessmom.com/sponsor/ Interested in becoming a sponsor of the Shameless Mom Academy? Email our sales team at sales@adalystmedia.com Learn more about your ad choices. Visit megaphone.fm/adchoices

ReachMD CME
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer

ReachMD CME

Play Episode Listen Later Dec 23, 2022


CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/ Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

Real Pink
Episode 206: The Passion Behind the Cause

Real Pink

Play Episode Listen Later Dec 19, 2022 14:49


Joining us on the show today is Ed Dandridge, Komen's Chair of the Board of Directors. With more than 30 years' experience in senior leadership roles with four Fortune 500 companies, Ed serves on executive management teams of leading global companies and works closely with Boards of Directors. Ed is here today to share what drives his passion in the fight against breast cancer. And to put his money where his mouth is, he is also going to share details about a Board match happening this month where Komen's Board of Directors are personally matching funds donated to Komen. Ed, welcome to the show!

ASCO Guidelines Podcast Series
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline

ASCO Guidelines Podcast Series

Play Episode Listen Later Dec 15, 2022 13:51


Dr. Emrullah Yilmaz reviews the latest evidence and recommendations for health care providers on biomarker testing and immunotherapy for head and neck cancers. He discusses the ASCO Expert Panel's recommendations for biomarkers for the selection of patients with head and neck squamous cell carcinoma for anti-PD-1 immune checkpoint inhibitor therapy. Additionally, he reviews recommended treatment options, including first-line treatment based on PD-L1 status, therapies for platinum-refractory disease, options for patients with nasopharyngeal cancer, the role of radiation therapy for oligometastatic head and neck cancer, and immunotherapy for rare head and neck cancers. Dr. Yilmaz also explores future areas of research for therapeutic options for patients with head and neck squamous cell carcinoma. Read the full guideline, “Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline” at www.asco.org/head-neck-cancer-guidelines. TRANSCRIPT Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast series, brought to you by the ASCO Podcast Network; a collection of nine programs, covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows, including this one, at: asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Emrullah Yilmaz, from Cleveland Clinic in Cleveland, Ohio, lead author on, 'Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline'. Thank you for being here today, Dr. Yilmaz. Dr. Emrullah Yilmaz: Thank you so much. Brittany Harvey: Then first, I'd like to note that ASCO takes great care in the development of its guidelines, and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The full conflict of interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. Yilmaz, do you have any relevant disclosures that are directed related to this guideline topic? Dr. Emrullah Yilmaz: No, I don't have a relevant disclosure. Brittany Harvey: Thank you. Then let's dive right into this guideline. So, generally, what is the purpose and the scope of this guideline? Dr. Emrullah Yilmaz: Immunotherapy with anti-PD-1 immune checkpoint inhibitors has become one of the most important treatment options for patients with recurrent metastatic head and neck cancers. And in the last few years, there has been new studies leading to new indications such as combinations with chemotherapy, or single-agent immunotherapy in the first-line treatment. And moreover, several studies also shown the effectiveness of immunotherapy for patients with nasopharyngeal carcinoma. All these advances in this complex disease group made it necessary to have an evidence-based guideline. So, that was the basis of building this guideline. Brittany Harvey: Understood. And then this evidence-based guideline addresses six clinical questions. So, I'd like to review the key recommendations for each of those questions for our listeners. So, let's start with the first question. What did the expert panel recommend regarding biomarkers for selecting patients with head and neck squamous cell carcinoma for anti-PD-1 immune checkpoint inhibitor therapy? Dr. Emrullah Yilmaz: Biomarkers are key for selection of treatment for immunotherapies, especially for the first-line treatment for head and neck cancer patients. PD-L1 is measured by immunohistochemistry and reported as Combined Positive Score, CPS, or Tumor Proportion Score, TPS. CPS is slightly different than TPS, and it includes lymphocyte and macrophage PD-L1 expression, in addition to tumor cells. Head and neck cancer studies have shown that CPS is a better marker for predicting response to immune checkpoint inhibitors, and key head and neck trials started to use CPS for reporting PD-L1 status. Therefore, we recommend CPS for recurrent metastatic head and neck cancers for PD-L1 reporting. This also makes it important for the oncologists to have a communication with the pathologists to make sure the right PD-L1 scoring is reported for head and neck cancer patients. Tissue tumor mutation burden is another emerging biomarker when CPS is not available, or for rare head and neck tumors, tumor mutation burden can be used as a biomarker as well. Brittany Harvey: Great. And then based on that PD-L1 status that you just mentioned, what is the optimal first-line treatment regimen for patients with recurrent or metastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: If PD-L1 is positive, which is CPS more than one, there are two different options. Both pembrolizumab, single agent or pembrolizumab plus chemotherapy with platinum and 5-Fluorouracil can be offered. KEYNOTE-048 study showed an overall survival benefit with pembrolizumab alone for patients with CPS more than one, which was greater for the patients with CPS 20 or more. However, the pembrolizumab plus chemotherapy has showed benefit for the patients regardless of the PD-L1 status. So, if an early response is needed for a patient with high disease burden, pembrolizumab with chemotherapy could be an option, even if the PD-L1 is positive. For patients with negative PD-L1, which is CPS less than one, we recommend pembrolizumab and chemotherapy. There was a recent subgroup analysis of KEYNOTE-048 for CPS-low patients. Patients with CPS less than one subgroup did not have significant survival difference with pembrolizumab plus chemotherapy when compared to cetuximab plus chemotherapy. This included a small number of patients, and this study was not powered to look at this subgroup, but cetuximab and chemotherapy can also be considered in the PD-L1 negative patient. Brittany Harvey: Understood. It's important to recognize which patients benefit from these treatments more than others in different subgroups. So, following that, what is the effect of immunotherapy compared to other systemic treatments in platinum-refractory recurrent, or metastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: Platinum-refractory disease is defined as recurrence within six months of platinum-based chemotherapy. And effectiveness of immunotherapy was actually proven in this disease group first, several years ago. The effectiveness of immunotherapy as a single agent was proven in two similarly designed phase III trials in this setting. CheckMate 141 trial compared nivolumab to standard-of-care methotrexate, cetuximab, or docetaxel, and KEYNOTE-040 trial compared pembrolizumab to similar standard-of-care agents. And both studies showed overall survival benefit when compared to standard-of-care systemic agents, and the responses were independent from the PD-L1 expressions. So, nivolumab or pembrolizumab, are options as single-agent immunotherapy treatments for the patients with platinum-refractory head and neck squamous cell carcinoma, regardless of their PD-L1 expression. Brittany Harvey: Understood, and thank you for getting into those options for those patients. Getting into the specifics for nasopharyngeal carcinoma, what did the panel recommend regarding the role of immunotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma? Dr. Emrullah Yilmaz: So, the combination of immunotherapy with cisplatin and gemcitabine was shown to be effective in first-line treatment of recurrent metastatic nasopharyngeal carcinoma, in several phase III studies from Asia in the last few years. JUPITER-02 study used toripalimab, CAPTAIN-1 study used camrelizumab, and RATIONALE-309 study used tislelizumab in combination with cisplatin and gemcitabine in the first-line treatment, and all these studies showed progression-free survival benefit with addition of immunotherapy to chemotherapy. Since these agents are not available in the United States as of now, our panel members recommend that pembrolizumab or nivolumab may be offered in combination with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. But the role of immunotherapy in the platinum-refractory nasopharyngeal carcinoma without the prior immunotherapy use is not well established yet. There are phase II studies that have shown that responses to immunotherapy are comparable to chemotherapy with a better safety profile. So, single-agent immunotherapy could be considered in a platinum-refractory setting if a PD-1 inhibitor was not used before. Brittany Harvey: Those are excellent points that you just made. So, following that, the next question that the panel considered is, what is recommended regarding the use of radiation therapy in combination with immunotherapy versus immunotherapy alone, for the treatment of locoregionally recurrent or oligometastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: This is a great question, and radiation therapy is used a lot in head and neck cancers for different purposes. And immunotherapy and SBRT combinations were not shown to increase efficacy for abscopal effect for the treatment of oligometastatic disease in head and neck cancers. So, radiation therapy should not be given to increase the effectiveness of immunotherapy in recurrent metastatic head and neck cancers. However, there are several ongoing studies to evaluate the efficacy of radiation such as SBRT with immunotherapy for locoregional recurrence. So, although radiation therapy is safe to give the patients with recurrent and metastatic cancers, with immunotherapy, it should be considered for palliation or local control until the results of these trials are available. Brittany Harvey: Great. And yes, we'll look forward to the results of those trials to find some more definitive results for these patients. So, then, the last clinical question that the panel addressed, what is recommended for the role of immunotherapy for rare head and neck cancers? Dr. Emrullah Yilmaz: The role of the immunotherapy for rare head and neck cancers depends on the biomarkers. KEYNOTE-158 study has shown the effectiveness of pembrolizumab in advanced cancer patients, which included different types of cancers with high tissue TMB defined as more than 10 mutations per megabase. And looking at the results from that study for the patients with advanced rare head and neck cancers with limited treatment options, such as, salivary gland cancers or sinonasal cancers, if high TMB, which is Tumor Mutational Burden, is identified, then pembrolizumab may be considered for those patients. And pembrolizumab was also shown to have activity in salivary gland cancer patients expressing more than 1% PD-L1. So, that makes it an option for these patients as well. Brittany Harvey: It sounds like understanding the biomarker status of these patients with rare head and neck cancers is essential for determining their therapy options. I want to thank you so much for reviewing all of those recommendations. So, in your view, Dr. Yilmaz, what is the importance of this guideline, and how will it impact clinicians and patients with head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: This guideline was written by panel members, experts in their field, including medical oncologists, radiation oncologists, head and neck surgeons, pathologists, and radiologists. It is really important for oncologists to communicate the treatment options to their patients clearly while planning treatment of head and neck cancers. So, this guideline can help the clinicians to provide evidence-based resource when to use the immunotherapy for their head and neck cancer patients. So, that can be really helpful to the clinicians. Brittany Harvey: Excellent. Yes, it's important to have a multidisciplinary group working on these guidelines to help clinicians in all capacities. Finally, what outstanding questions or ongoing research are you interested in for future therapeutic options in head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: Our guideline focuses on recurrent metastatic head and neck cancers since it is the only area where the immunotherapy is approved as of now. We've had a few studies in the curative intent setting, which has not shown the benefit of addition of immunotherapy to radiation therapy, or chemoradiation. There's still several studies ongoing to investigate the effectiveness of immunotherapy in the curative intent setting, and the neoadjuvant setting, or adjuvant setting, or different combinations with the radiation therapy, with the immunotherapy, with the different sequences. So, it will be interesting to see the results of those studies in the future. So, that might be another area that the field might be moving in the future. There are also studies ongoing to improve effectiveness of the immunotherapy in the recurrent and metastatic disease. Chemoimmunotherapy seems to be among the strongest systemic treatment options right now that we have, but there are several other combination strategies that are being developed combined with the PD-1 inhibitors, including combinations with EGFR inhibitors, angiogenesis inhibitors, intratumoral injections, vaccine developments, and there are a lot of different novel checkpoint inhibitors being developed. So, the field is advancing in that area as well. So, those are the areas that research are ongoing at this point. Brittany Harvey: Definitely. We'll look forward to the results of those ongoing trials to inform future updates and future guidelines in this area. So, I want to thank you so much for all of your work that you put into developing these evidence-based guidelines and thank you for your time today, Dr. Yilmaz. Dr. Emrullah Yilmaz: Thank you so much. Brittany Harvey: And thank you to all of our listeners for tuning to the ASCO Guidelines podcast series. To read the full guideline, go to: www.asco.org/head-neck-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in iTunes or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe, so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.  

Real Pink
Episode 203: Real Talk: Living With Metastatic Breast Cancer And The Holidays

Real Pink

Play Episode Listen Later Dec 12, 2022 54:30


This is Real Talk, a new podcast series where we're going to break down the stigmas and feelings of embarrassment and talk openly and honestly about just how difficult breast cancer can be – from diagnosis to treatment, to living with metastatic breast cancer, to life after treatment ends. Today I'm joined by three women living with metastatic breast cancer. It is my pleasure to welcome Pam Kohl, who, along with Ann Camden and Katie Mackin, are getting real about the holidays and their thoughts and feelings this time of year.

Yale Cancer Center Answers
The Role of Surgical Oncology in Treating Metastatic Cancers

Yale Cancer Center Answers

Play Episode Listen Later Dec 11, 2022 29:00


The Role of Surgical Oncology in Treating Metastatic Cancers with guest Dr. Kiran Turaga December 11, 2022 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Breastcancer.org Podcast
Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer

Breastcancer.org Podcast

Play Episode Listen Later Dec 9, 2022 8:59


2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla. Listen to the episode to hear Dr. Hurvitz explain: overall survival and progression-free survival results severe side effects of Enhertu how the researchers managed any severe lung problems that developed in people receiving Enhertu

Breastcancer.org Podcast
What Patients Want Doctors and Researchers to Know About Living With Metastatic Breast Cancer

Breastcancer.org Podcast

Play Episode Listen Later Dec 7, 2022 10:53


A number of issues affecting people diagnosed with metastatic breast cancer, including financial toxicity, support, and early palliative care, were discussed at an educational session on the first day of the 2022 San Antonio Breast Cancer Symposium. Metastatic patient advocates Christine Hodgdon and Stephanie Walker talked about what they want researchers and clinicians to know about day-to-day life with metastatic disease. Listen to the episode to hear Christine and Stephanie discuss: why the patient perspective is important if and how the patient perspective is taken into account as new treatments are developed what they hope happens as a result of their participation in the session

Real Pink
Episode 202: High Risk for Breast Cancer? Create a Plan!

Real Pink

Play Episode Listen Later Dec 5, 2022 16:28


Everyone is at risk of breast cancer, and some of us are at a higher risk than others. Learning about your breast cancer risk can empower you to make important breast care decisions to take charge of your health. Today's guest lost her mother to breast cancer 20 years before she had her first mammogram. The results of that first mammogram revealed something suspicious, which was a huge wake up call for her and caused her to speak with her doctors about preventative options. Here today to share what she learned and the steps that she is taking to prevent the development of breast cancer is Colleen Boraca.

ReachMD CME
The Current and Future Role of Immuno-Oncologic Agents in Early-Stage, Locally Advanced, and Metastatic NSCLC

ReachMD CME

Play Episode Listen Later Nov 30, 2022


CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-current-and-future-role-of-immuno-oncologic-agents-in-early-stage-locally-advanced-and-metastatic-nsclc/14493/ Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen in as Drs. Debora Bruno, Gilberto Lopes, and Solange Peters discuss the most recent data for immunotherapy in early-stage, locally advanced, and metastatic NSCLC.

Frankly Speaking About Cancer with the Cancer Support Community
What You Need to Know About Advanced or Metastatic Bladder Cancer

Frankly Speaking About Cancer with the Cancer Support Community

Play Episode Listen Later Nov 29, 2022 58:55


Over the last decade, the number of treatment options for patients with advanced cancers has greatly expanded. In this episode, we look at treatments currently available to patients diagnosed with advanced or metastatic bladder cancer and discuss ways to cope with this difficult diagnosis. Our guests are Dr. Daniel Geynisman and Monica Scanlan, BSN, RN, both of Fox Chase Cancer Center at Temple Health, and Rachel Saks, MSS, LSW, OSW-C, Senior Director, Education at the Cancer Support Community.

The Medbullets Step 2 & 3 Podcast
Oncology | Metastatic Cancer to Bone

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Nov 29, 2022 16:59


In this episode, we review the high-yield topic of Metastatic Cancer to Bone from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Lung Cancer Update
Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer

Lung Cancer Update

Play Episode Listen Later Nov 28, 2022 64:08


Featuring a discussion on the use of immunotherapy in the treatment of metastatic non-small cell lung cancer with Drs John Heymach and Sephen Liu, moderated by Dr Neil Love.

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer | Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Nov 28, 2022 64:09


Featuring perspectives from Drs John Heymach and Stephen Liu, including the following topics: Introduction (0:00) Current Immunotherapy-Based Strategies for Non-Small Cell Lung Cancer (NSCLC) (9:29) Future Directions in the Management of NSCLC (37:09) CME information and select publications

Real Pink
Episode 201: The Need for Clinical Trial Participation by Diverse Populations

Real Pink

Play Episode Listen Later Nov 28, 2022 21:11


Black women are less likely to participate in clinical trials than white women. We are going to discuss why that is and why it's so important for Black women to participate in clinical trials with Sheila Marie Johnson. We have welcomed her as a guest on the podcast before and are excited to have her back. Sheila, Welcome to the show!

The Armor Men's Health Hour
Bonus Episode: Dr. Trubek on PSMA: The Latest and Greatest Tool in Early & Metastatic Cancer Detection

The Armor Men's Health Hour

Play Episode Listen Later Nov 26, 2022 20:45 Transcription Available


In this episode, Dr. Mistry and Donna Lee are joined by Dr. Simon Trubek of Austin Radiological Association. As a radiologist specializing in nuclear medicine, Dr. Trubek injects radiopharmaceutical or radioactive substances into patients to help detect the presence and severity of cancer. Today, he is here to discuss PSMA, or Prostate Specific Membrane Antigen--a recently approved agent that significantly improves prostate cancer detection and treatment. In about an hour, Dr. Trubek's patients can come in and have an injection of PSMA that will help detect the presence and disease progression of slow-growing, metabolically inactive cancers like that of the prostate. Tune in to learn how PSMA is helping radiologists detect metastatic cancer by finding lymph nodes as small as 4mm in size! If you or someone  you love has had prostate cancer and is worried about a recurrence, please visit https://www.ausrad.com/pluvicto/ today to learn how PSMA could set your mind at ease!Voted top Men's Health Podcast, Sex Therapy Podcast, and Prostate Cancer Podcast by FeedSpotDr. Mistry is a board-certified urologist and has been treating patients in the Austin and Greater Williamson County area since he started his private practice in 2007.We enjoy hearing from you! Email us at armormenshealth@gmail.com and we'll answer your question in an upcoming episode.Phone: (512) 238-0762Email: Armormenshealth@gmail.comWebsite: Armormenshealth.comOur Locations:Round Rock Office970 Hester's Crossing Road Suite 101 Round Rock, TX 78681South Austin Office6501 South Congress Suite 1-103 Austin, TX 78745Lakeline Office12505 Hymeadow Drive Suite 2C Austin, TX 78750Dripping Springs Office170 Benney Lane Suite 202 Dripping Springs, TX 78620All content © 2022 Armor Men's Health.

Living Our Breast Lives
Grateful for Survival, but What About the Others?

Living Our Breast Lives

Play Episode Listen Later Nov 23, 2022 35:54


Join Wren and special guest, Cait Kelley as they have a very hard yet very necessary conversation about survivors guilt and what it's like to lose people they loved to Metastatic breast cancer. This Thanksgiving we honor these tremendous losses and with each and every day we are gifted on this Earth, we will continue to get loud and advocate for those who cannot any longer. We must continue to pass on their legacies and remain hopeful that one day, someday soon, MBC can go from awareness to action so more precious lives can be saved. Instagram: @livingourbreastlives

Real Pink
Episode 200: Happy 200th, Real Pink

Real Pink

Play Episode Listen Later Nov 21, 2022 20:07


Adam Walker has dazzled our listeners as the host of Real Pink for 200 episodes. In today's episode, Samantha Harris, our very first guest, returns to interview Adam. Tune in to hear Adam share his story and what he's learned over the past 200 episodes.

Real Pink
Episode 199: Real Talk: Talking to Your Children About Breast Cancer

Real Pink

Play Episode Listen Later Nov 14, 2022 38:56


This is Real Talk, a new podcast series where we're going to break down the stigmas and feelings of embarrassment and talk openly and honestly about just how difficult breast cancer can be – from diagnosis, to treatment, to living with metastatic breast cancer, to life after treatment ends. Today I'm joined by two survivors who are married with children. After learning they had breast cancer, they started thinking about how they'd share the news with their young children. What to say, what not to say, and how to explain what was happening to mom. Sheetal and Beverly let's get real about telling your children you have breast cancer. Welcome to the show. 

OncoPharm
Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?

OncoPharm

Play Episode Listen Later Nov 10, 2022 14:05


We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC. CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558 POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426 Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

Cleveland Clinic Cancer Advances
FDA Approved: Lutetium-PSMA for Metastatic Prostate Cancer

Cleveland Clinic Cancer Advances

Play Episode Listen Later Nov 10, 2022 18:28


Christopher Wee, MD, a medical oncologist from the Genitourinary Medical Oncology Program at Taussig Cancer Institute joins the Cancer Advances podcast to talk about therapies for metastatic prostate cancer. Listen as Dr. Wee discusses Lutetium-PSMA and the clinical trials that showed patients had better response rates and fewer toxicities when they got lutetium on top of their care.

The Armor Men's Health Hour
EP 607: Prostate Cancer, From the Manageable to the Metastatic: Dr. Sheinbein on Modern Radiation Therapy

The Armor Men's Health Hour

Play Episode Listen Later Nov 9, 2022 21:03


In this episode, Dr. Mistry and Donna Lee are joined by special guest Dr. Courtney Sheinbein from Texas Oncology. Dr. Sheinbein is a radiation oncologist who uses modern and cutting-edge radiation therapies to treat a range of cancers in the body. Although many people remember radiation treatment as the blunt tool it was in the past, recent innovations in oncology care have made radiation one of the most effective and precise tools available, reducing recurrence and increasing life span and quality of life for countless patients. Today, Dr. Sheinbein talks about the latest in cancer imaging and treatment, including proton treatment, SBRT, CyberKnife, and more! To schedule an appointment, visit Texas Oncology today online or call 512-687-2300. Voted top Men's Health Podcast, Sex Therapy Podcast, and Prostate Cancer Podcast by FeedSpotDr. Mistry is a board-certified urologist and has been treating patients in the Austin and Greater Williamson County area since he started his private practice in 2007.We enjoy hearing from you! Email us at armormenshealth@gmail.com and we'll answer your question in an upcoming episode.Phone: (512) 238-0762Email: Armormenshealth@gmail.comWebsite: Armormenshealth.comOur Locations:Round Rock Office970 Hester's Crossing Road Suite 101 Round Rock, TX 78681South Austin Office6501 South Congress Suite 1-103 Austin, TX 78745Lakeline Office12505 Hymeadow Drive Suite 2C Austin, TX 78750Dripping Springs Office170 Benney Lane Suite 202 Dripping Springs, TX 78620

Real Pink
Episode 198: An Olympian's Story of Feeling Betrayed by Her Body

Real Pink

Play Episode Listen Later Nov 7, 2022 18:11


Healthy lifestyle choices, such as being physically active, maintaining a healthy weight and eating a balanced diet are linked to a lower risk of breast cancer, yet no one knows exactly why one person gets breast cancer and another doesn't. Everyone is at risk. In fact, the two most common risk factors for breast cancer are being a woman and getting older. Today's guest was blessed with a body that had served her extremely well – it helped her win a bronze medal at the Olympic Games, to navigate a successful, decade long career on Wall Street and brought two healthy babies into the world. Despite being a top-level athlete, having no history of breast cancer in her family and not being a carrier of the BRCA genes, Lauren McFall Gardner was diagnosed with stage 3 breast cancer at the age of 40. She is here today to share her story and the impact that breast cancer had on her life and her vision of health.

MIB Agents OsteoBites
Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma

MIB Agents OsteoBites

Play Episode Listen Later Nov 4, 2022 57:07


Dr. Dan Regan discusses his OutSmarting Osteosarcoma funded work on Focal Adhesion Kinase (FAK) inhibition to improve losartan-sunitinib immunotherapy in metastatic osteosarcoma. - Dr. Dan Regan is an Assistant Professor at the Flint Animal Cancer Center at Colorado State University and he is one of our OutSmarting Osteosarcoma 2022 grant recipients. Dr. Regan received his DVM degree from the University of Georgia and subsequently completed his residency training in veterinary anatomic pathology and PhD in the Department of Microbiology, Immunology, and Pathology (MIP) at Colorado State University. In 2018 he joined the Flint Animal Cancer Center and MIP in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. The focus of Dr. Regan's laboratory is to increase our understanding of the interplay between the immune system and (non-immune) tumor stroma, and how these compartments of the tumor microenvironment promote metastasis as well as respond to and mediate extrinsic mechanisms of resistance to anti-cancer therapy. To investigate this area of cancer biology, his laboratory utilizes a combination of in vitro 3-dimensional tumor co-culture models and animal models, focusing on breast and bone cancer (osteosarcoma). Dr. Regan also has a strong interest in comparative oncology and leveraging naturally occurring cancers in dogs as both a surrogate and intermediary model to evaluate and validate his laboratory's investigations into the tumor microenvironment. In collaboration with the laboratory of Dr. Steve Dow, his lab conducted immunotherapy clinical studies in dogs with spontaneous osteosarcoma and these study results have led to a phase I clinical trial in children with osteosarcoma. His lab's continued long-term research goal is to fully elucidate the mechanisms by which tumors prime non-malignant host stromal cells of distant organs to promote their metastasis and chemo-resistance, in order to identify novel targets for host-directed stromal therapies which “poison the soil” for effective combination with conventional tumor cell targeted drugs. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

Inside the Lab
The Molecular Biomarker Revolution in Metastatic NSCLC

Inside the Lab

Play Episode Listen Later Nov 3, 2022 44:16


During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty will discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC.  In addition, they will address how to integrate next generation sequencing (NGS) into your biomarker testing workflows and optimize its use for patients.  Finally, they will share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients.  The activity offers 1.0 CME/CMLE credit.  The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.   Learning ObjectivesUpon completion of this activity, you should be able to:·         Describe ongoing investigational efforts regarding emerging biomarkers in metastatic NSCLC ·         Utilize NGS to identify current and emerging biomarkers to predict response to personalized therapies for patients with metastatic NSCLC ·         Employ strategies for optimizing workflows and turnaround times for NGS ·         Discuss the science behind resistance mechanisms in patients with metastatic NSCLC ·         Recognize the use of emerging I-O combination therapies and potential biomarkers in patients with metastatic NSCLC ·         Develop ways to improve communication among pathologists, oncologists, and other members of the multidisciplinary lung cancer care team FacultyDiana N. Ionescu MD, FRCPC, FCAP Consultant Pathologist and Medical Lead Anatomical Pathology Medical Director BC Cervical Cancer Screening Laboratory Medical Director Clinical Trials, BC Cancer Laboratories Clinical Professor of Pathology, University of British Columbia Doru Paul, MD, PhDAttending Physician, Division of Hematology and Medical Oncology Weill Cornell and New York Presbyterian Hospital  Faculty DisclosuresThe following Panel/Faculty members have relevant financial relationships to disclose:  | Faculty Member | Ineligible Company | For what role? | Diana Ionescu, MD | AstraZeneca, Bayer, BMS, Merck, Pfizer, Roche | Consultant, Consultant, Consultant, Consultant, Consultant, Consultant Dr. Paul has no relevant financial relationships to disclose All of the relevant financial relationships listed for these individuals have been mitigated  Commercial SupportFunded by an independent educational grant from AstraZeneca Pharmaceuticals

Real Pink
Episode 197: Managing Breast Cancer Like a Boss

Real Pink

Play Episode Listen Later Oct 31, 2022 16:10


Caregivers provide much-needed support for those going through breast cancer. This can be in the form of emotional support such as listening or giving a hug; in the form of practical help like driving to and from doctor appointments, cooking, cleaning or grocery shopping; and through providing informational support like gathering data or the latest news on breast cancer. Mountains of paperwork, medical information and appointments can be overwhelming and a lot for families to manage, especially while they are also trying to ensure that their loved ones feel cared for and understood. Today's guest is a powerhouse entrepreneur – she was the co-founder of designer jeans brand True Religion, is a 25-year fashion industry veteran, has launched five style brands, develops and produces film and television projects with a social conscience, wrote a book, is a philanthropist and also a mentor to young fashion designers. She is also a triplet and was a caregiver to her mom throughout her battle with metastatic breast cancer. Here today to share her story and how she helped manage her mom's breast cancer journey like a boss is Kym Gold.

Research To Practice | Oncology Videos
Melanoma | Oncology Today with Dr Neil Love: BRAF-Mutant Metastatic Melanoma

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2022 53:47


Featuring an interview with Prof Axel Hauschild, including the following topics: Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00) Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23) Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58) Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36) T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23) Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13) Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05) Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25) CME information and select publications

Research To Practice | Oncology Videos
Melanoma | Oncology Today with Dr Neil Love: BRAF-Mutant Metastatic Melanoma (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 27, 2022 37:00


Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics: Emerging data with targeted agents for metastatic melanoma (0:00) Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13) Comparing targeted agents and immune checkpoint inhibitors (17:34) Current melanoma guidelines and other therapies under investigation (24:09)  CME information and select publications

Oncology Today with Dr Neil Love
BRAF-Mutant Metastatic Melanoma with Prof Axel Hauschild

Oncology Today with Dr Neil Love

Play Episode Listen Later Oct 27, 2022 54:27


Professor Axel Hauschild from Kiel University in Kiel, Germany, discusses recent therapeutic advances in the treatment of metastatic melanoma with BRAF mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayBRAFMelanoma22).

Beyond The Ribbon
Finding Hope in Metastatic Cancer

Beyond The Ribbon

Play Episode Listen Later Oct 25, 2022 52:52


Finding Hope in Metastatic Cancer - Learn how finding your community can make all the difference.

JAMA Network
JAMA Oncology : Prostate-Specific Antigen Screening Rates and Metastatic Prostate Cancer Incidence in the VHA

JAMA Network

Play Episode Listen Later Oct 24, 2022 16:36


Interview with Brent S. Rose, MD, author of Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. Hosted by Jack West, MD. Related Content: Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities

JAMA Network
JAMA Oncology : Prostate-Specific Antigen Screening Rates and Metastatic Prostate Cancer Incidence in the VHA

JAMA Network

Play Episode Listen Later Oct 24, 2022 16:15


Interview with Brent S. Rose, MD, author of Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. Hosted by Jack West, MD. Related Content: Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities

Real Pink
Episode 196: Understanding Your Risk Through Genetic Counseling and Testing

Real Pink

Play Episode Listen Later Oct 24, 2022 16:49


Everyone is at risk of breast cancer, but some are at higher risk than others. Understanding your risk starts with learning about your own risk factors and starting a conversation with your doctor. Gathering your family health history to know your risk of developing health problems can help you determine whether to pursue genetic counseling and testing. We are going to discuss these topics in depth today with Natasha Mmeje, Komen's Director of Community Education and Outreach. Welcome to the show, Natasha!

Real Pink
Episode 195: Real Talk: Breast Cancer's Mental Impact

Real Pink

Play Episode Listen Later Oct 17, 2022 16:58


This is Real Talk, a new podcast series where we're going to break down the stigmas and feelings of embarrassment and talk openly and honestly about just how difficult breast cancer can be – from diagnosis, to treatment, to living with metastatic breast cancer, to life after treatment ends. Today, we're getting real about the mental and emotional impact of breast cancer. Breast cancer affects everyone differently. Whether you're in treatment or have just completed treatment, almost everyone will experience changes. Life changes and coping with those changes may not come easy. It is common for people diagnosed with breast cancer to experience depression, anxiety, fear and mental or emotional distress. Just talking about these experiences and the long-term challenges of breast cancer helps to normalize the lived experiences of millions of people who have been impacted by the disease. Cati Diamond Stone is joining me today. She is vice president of community health at Susan G. Komen. Cati, taking care of your mental health and getting mental help is such a great topic. Welcome to the show.

Real Pink
Episode 194: Carlita McIlwain Remembers Her Mother as a Service-Driven Force of Nature

Real Pink

Play Episode Listen Later Oct 14, 2022 27:11


Although metastatic breast cancer cannot be cured today, it can be treated. Treatment focuses on extending life and maintaining quality of life, both of which were incredibly important to Sylvia Proctor as she was living with metastatic breast cancer. Unfortunately, Sylvia passed away from MBC just before Mother's Day last year. Her daughter, Carlita McIlwain (MAC-ILL-WAYNE), remembers her mother as an entrepreneur at heart who successfully ran more than 10 businesses during her lifetime while also working full-time. Her life was defined by her devotion to her Catholic faith and her Native American/African American family. Carlita is here today to share her mother's story, which has fueled her passion to give back and help find the cures for breast cancer. It is her hope that her work will help future generations – both in her family and in her cultures.

Real Pink
Episode 193: Funding the Future of Groundbreaking MBC Research

Real Pink

Play Episode Listen Later Oct 13, 2022 26:18


Susan G. Komen knows that even one more day without a cure for metastatic breast cancer is one day too many when lives are at stake. MBC is the most advanced stage of the disease. Though there are treatments to extend life, there is no cure. That's why this year, Komen is going one step further to raise an extra $1 million to fund the first ever MBC Excellence in Research Award. Here today to tell us about this $1 Million Challenge and some of the promising new research the grant could fund is Dr. Kim Sabelko, Komen VP of Scientific Strategy and Programs.

The Fellow on Call
Episode 033: Lung Cancer Series, Pt. 10: Metastatic NSCLC with driver mutations

The Fellow on Call

Play Episode Listen Later Oct 12, 2022


Lung cancer is one of the most commonly diagnosed type of cancer and so it is fitting that we start the first of our disease-specific oncology series with this diagnosis. This week, we continue our discussion on metastatic non-small cell lung cancer, focusing on NSCLC with driver mutations. * The approach to treatment of a patient with widespread metastatic NSCLC (mNSCLC) is very different than a patient without distant disease, which highlights why we do what we do:- Important to complete staging (discussed in prior episodes) to determine the extent of disease- Important to check molecular testing (looking for mutations in the cancer cells) and IHC for tumor proportion score (TPS) helps determine treatment options - If your molecular testing is identified in a driver mutation gene, there are targeted options for this! *Driver mutations are predictive of response to an oral therapy and a LACK of response to immune therapy (particularly in EGFR and ALK mutated patients) * EGFR Mutation:- Pay attention to the types of mutation in EGFR (not all are the same):-- Exon 19 deletion -- Exon 19 L858R-- Exon 21 T790M-- Exon 20 Insertion (Osimertinib [see below] cannot be used for this mutation)- Osimertinib is first-line standard of care for patients with EGFR-- Used to be a second-line agent. Many patients with EGFR mutations receiving earlier generation TKIs would develop resistance and when these tumors were sequenced, they would have Exon 21 T790M mutations. Osimertinib was effective even with this mutation and had superior overall survival data compared to chemotherapy (AURA3 Trial)--Now it is used in first-line setting for patients with EGFR mutation based on the FLAURA trial --- In this study, patients received osimertinib as first line vs. older generation EGFR-targeting TKIs (erlotinib or gefitib) and Osimertinib had better outcomes: ---- Showed that the median OS was 38.6 months with Osi vs. 31.8 months; also improved brain penetration! ---- Also effective in patients with metastatic disease to the brain: ----- Only 6% of patients had CNS progression with Osi vs. 15% with others- What if a patient is on Osi and later develops new brain mets?-- If there is progression within just the brain (and good control in other sites of the body) you can refer patient to Radiation Oncology for SRS-- Remember, based on discussion with Dr. Osmundson in our RadOnc lectures (Episode 028), it is important to HOLD Osimertinib if patient is going to get radiation to minimize the side effects- What is patient had progression of disease in several sites throughout the body?-- Management is less straightforward. -- In many of these cases, you can consider:--- Consolidative radiation - If small amounts of disease--- Changing therapy - If there has been widespread progression; likely would change to chemotherapy (without IO, since lower predictive response to IO with EGFR mutation)---- No clear guidelines if you should continue the TKI---- Remember that IO + TKIs can cause increased risk of side effects, such as pneumonitis and hepatitis. DO NOT DO THIS!* ALK Mutation:- There are many options for ALK mutations-- The first generation drug is crizotinib--- Lots of side effects —> “It is crazy to start with crizotinib”--- Studies for later generation TKIs were compared to crizotinib -- Many people today will use third generation ALK-inhibitor alectinib (Important trials: ALEX Trial and J-ALEX Trial)--- With alectinib, PFS 34.8 months, RR 83%, less CNS progression (12% vs 45%)--- 5 year OS rate 62.5%- What to do with disease progression while on ALK inhibitor?-- In ALK, you can actually switch to another ALK inhibitor and many will respond well--- Of course, with each change, you may expect not as great of a response * Lots of other mutations!- TFOC recommends just looking these up!-- Link to NCCN Guidelines on NSCLC; Page 41 has full list!- Another way to think about this, when do we NOT do TKIs as first line: -- KRAS G12C-- EGFR Exon 20 Insertion-- HER2- How do you counsel a patient when considering/starting a TKI? -- Patients with highest chance of having a targeted mutation are younger non-smokers with adenocarcinoma-- Set expectations: great outcomes overall, but still not a cure. -- Remembering the drugs: All TKIs usually end in “-nib” -- In general, the way we recommend remembering this: “Fatigue, GI, Derm (skin/nail changes)”; rarely pneumonitis References:* AURA3 Trial - https://www.nejm.org/doi/full/10.1056/NEJMoa1612674Established osimertinib was better than chemo for patients with EGFR mutation and acquired Exon 21 T790M resistance mutation* FLAURA Trial - https://www.nejm.org/doi/full/10.1056/nejmoa1713137 Established osimertinib as first-line agent for patients with EGFR mutation * ALEX Trial - https://www.nejm.org/doi/full/10.1056/nejmoa1704795Helped establish alectinib as superior for ALK mutations compared to crizotinib * J-ALEX Trial - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30565-2/fulltextHelped establish alectinib as superior for ALK mutations compared to crizotinib * NCCN Guidelines on NSCLC - https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google PodcastLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Real Pink
Episode 192: Dr. Julie Palmer Researches Breast Cancer in Her Sister's Memory

Real Pink

Play Episode Listen Later Oct 12, 2022 23:28


This is a promising time in metastatic breast cancer research. Many new treatments for MBC are under study and treatment is improving, allowing families more time with their loved ones. Today's guest became a breast cancer researcher after her mother was diagnosed with breast cancer. Following her late sister's MBC diagnosis and passing, she has dedicated her career to research that will help to identify women who are at especially high risk of metastatic breast cancer and to identifying lifestyle changes that may improve quality of life for women living with metastatic breast cancer. Here today to share their story in her sister's memory and how her family history fuels her passion in searching for cures is Komen Scholar Dr. Julie Palmer.

Real Pink
Episode 191: Finding Joy Again After Losing Jen

Real Pink

Play Episode Listen Later Oct 11, 2022 40:43


The loss of a partner or spouse is a traumatic event in the moments leading up to the loss are traumatic as well. While family and friends can be strong sources of support for those with breast cancer, support for their loved ones and caregivers is also crucial. Today's guest lost his wife, Jennifer, to metastatic breast cancer when he was 38 years old. Here today to share their story a decade later and what his healing process has been like in those years since is Angelo Merendino.

Real Pink
Episode 190: An Eternal Sisterhood: Tara Coppedge Remembers Rhonda Howell

Real Pink

Play Episode Listen Later Oct 10, 2022 15:54


Tara Coppedge never imagined that one of her assignments as a reporter would result in forming a deep bond with Rhonda Howell, who had already been living with metastatic breast cancer for two years when they met in 2017. The two women automatically clicked and forged a deep friendship that continued until Rhonda passed away in January of this year. The impact of losing a friend or loved one is profound and often offers life lessons from the experience, such as how to be brave and to never to take any relationships for granted. Tara is here today to share the story of their friendship and how losing Rhonda changed her life and fueled her inspiration to continue making a difference in the breast cancer community.